From Kim Thompson, CEO Kraig Biocraft Laboratories, Inc. (PINKSHEETS: KBLB);

Dear Kraig Biocraft Laboratories Community,

For the past five years, I have been privileged to be a part of the legacy and vision of a truly revolutionary biotechnology company, Kraig Biocraft Laboratories, but this is, by far, the most exciting holiday season for members of the Kraig team and Kraig shareholders.

2010 has already been a tremendous year, as we have made scientific history with our development of twenty separate lines of transgenic silkworm. Among the products which we have invented and are producing in the laboratory is "Monster Silk™", a genetically engineered composite of spider silk and silkworm silk which is significantly stronger and more flexible than commercial silk. While we still have a few weeks to go in 2010, I wanted to share with you some thoughts about our corporate state of affairs, because I firmly believe that we are destined for even greater achievements in 2011.

We are rapidly moving towards commercialization and are solidly committed to executing a focused plan of developing strategic partnerships, as well as merger and acquisition opportunities, synced to our current technologies and the anticipated future generations of spider silk technologies. We have always believed that the shortest and surest path to commercialize the products we develop in the laboratory is through partnership with companies which already possess significant market share in our target markets.

Our aggressive commercialization plan benefits from the addition of two world class experts in corporate growth, Henry Wendt and Raymond Kutsunai, to the Business Advisory Board. I believe that their leadership and experience, especially in the area of mergers and acquisitions, will make a significant contribution to the commercialization of our breakthroughs in biotechnology and polymer science. I also believe that the addition of these outstanding team members confirms that we are headed in the right direction. We have also identified a potential Business Advisory Board member who has impeccable technical textile market expertise, and we anticipate making an announcement in the near future.

Kraig remains on track for product optimization and commercialization. I believe that our partnership, merger and/or acquisition prospects are very strong. I also believe our aggressive business model strongly leverages the Company's position, and will reap exciting results in 2011.

At the same time I have taken steps to accelerate our research and development work in the laboratory to leverage what we have already invented and discovered into a second generation of new technologies. We anticipate that this second generation technology will be unveiled in 2011.

We remain committed to working towards the rapid commercialization of the most revolutionary products imaginable. 2011 will be an exciting time for Kraig Biocraft Laboratories, and I personally am anticipating the growth of our company in the New Year. Our shareholders have come to appreciate the patience and commitment required to make Kraig a world class technical textiles leader. I would like to take this opportunity to thank them, as well as our dedicated Scientific Advisory Board and Business Advisory Board, for their ongoing support.

Lastly, I extend my sincere best wishes to you and your families for the holidays. So, on behalf of Kraig Biocraft Laboratories, I would like to wish you a Happy Hanukah and a Merry Christmas, and a healthy and prosperous New Year!

Kim Thompson, CEO Kraig Biocraft Laboratories, Inc.

To learn more about Kraig Biocraft Laboratories please visit www.KraigLabs.com and go to the video page to see the extraordinary accomplishments of this small biotechnology company.

Statements in this press release about the company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "hopes," "develops," "researching," "research," "potential," "implications," "could" or other words or phrases of similar import. Similarly, statements in this release that describe the Company's business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company's financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

Contact: Ben Hansel (720) 288-8495 Email Contact

Kraig Biocraft Laborator... (QB) (USOTC:KBLB)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Kraig Biocraft Laborator... (QB) Charts.
Kraig Biocraft Laborator... (QB) (USOTC:KBLB)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Kraig Biocraft Laborator... (QB) Charts.